Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma

Bart Barlogie, Maurizio Zangari, Vanessa Bolejack, Klaus Hollmig, Elias Anaissie, Frits van Rhee, Mauricio Pineda-Roman, Abid Mohiuddin, John Crowley, Guido Tricot

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Background: Complete response has been considered a surrogate for favorable long-term outcome in multiple myeloma. Data on the impact of the duration of response on prognosis are lacking. Patients and methods: Of the 899 patients enrolled in Total Therapy trials (Total Therapy 1, N=231; Total Therapy 2, N=668), 254 survived for > 5 years. The prognostic impact of continuous (Rc) versus discontinuous (Rd) 4-year remission after 5-year survival was examined along with laboratory features present at baseline and at 5 years. Results: Most baseline prognostic features were evenly distributed among Rc and Rd groups; however, a greater proportion of Rc patients were enrolled in Total Therapy 2 (60%) compared with Rd (19%; P < 0.001). Twelve-year survival (7 years after the 5-year landmark) was 66% with Rc and only 30% with Rd. Hypodiploidy and deletion 13, present in 24 patients at baseline, were associated with a 12-year survival of only 20%. Among the 200 patients lacking these cytogenetic abnormalities, Rc (n=141) defined a superior 12-year survival rate of 70% versus 35% among those with Rd (n=59). Initial quality of response (complete response) or having received the scheduled tandem transplantations did not affect post-5-year survival. Conclusion: Five-year Rc appears to be an important prerequisite for prolonged subsequent overall survival.

Original languageEnglish (US)
Pages (from-to)469-474
Number of pages6
JournalClinical Lymphoma and Myeloma
Volume6
Issue number6
DOIs
StatePublished - May 2006

Keywords

  • Chemotherapy
  • Cytogenetic abnormality
  • Hypodiploidy
  • Immunomodulatory agents
  • Total Therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma'. Together they form a unique fingerprint.

  • Cite this

    Barlogie, B., Zangari, M., Bolejack, V., Hollmig, K., Anaissie, E., van Rhee, F., Pineda-Roman, M., Mohiuddin, A., Crowley, J., & Tricot, G. (2006). Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. Clinical Lymphoma and Myeloma, 6(6), 469-474. https://doi.org/10.3816/CLM.2006.n.027